CRBP: I think this is one of the most overlooked biotech catalysts of 2026

I've spent the last few months digging into Corbus Pharmaceuticals ($CRBP) and it seems the upcoming obesity readout is one of the highest risk/reward catalysts currently in biotech.

This is **not financial advice.** There is absolutely a chance the data disappoints. But I think the market is greatly underestimating what positive results could mean.

As most know GLP-1s are dominating obesity market currently. But there is another pathway that has also already been proven to work: **CB1 inhibition**.

Back in the 2000s, Sanofi's rimonabant produced meaningful weight loss and metabolic benefits. The problem wasn't efficacy, it was that the drug entered the brain and caused psychiatric side effects, leading to its withdrawal.

CRBP's drug, **CRB-913**, was designed to solve that problem.

Unlike rimonabant (and apparently with substantially greater peripheral restriction than Novo Nordisk's monlunabant in preclinical testing), CRB-913 was engineered to stay largely out of the brain while targeting peripheral CB1 receptors responsible for many of the metabolic effects.

The first human data were encouraging.

Phase 1 showed:

* 2.9% placebo-adjusted weight loss in only **14 days**
* No meaningful neuropsychiatric safety signals on daily C-SSRS, PHQ-9 and GAD-7 assessments
* No nausea, vomiting or constipation reported
* Evidence that weight loss continued to deepen over time rather than plateauing.

Obviously, 12 obese patients over two weeks doesn't prove that the drug works.

**That's why the current study is so important.**

The ongoing CANYON-1 trial enrolled roughly **240 patients** in a 12-week dose-ranging study and it is expected to report topline data in September 2026. This is the first dataset that can really answer whether the Phase 1 signal was real.

What I think the market is missing is that this isn't just another obesity startup with a me-to drug.

If CRB-913 shows:

* clinically meaningful weight loss,
* clean psychiatric safety,
* and a mild GI profile,

then it potentially brings back to life an entire drug class that most investors wrote off years ago after Novo Nordisk’s failure. And the best part for the company is that their drug is by far the most advanced next gen version there is. So if it proves itself in September it could have almost a monopoly for many years to come.

For anyone who wants to do their own DD here are couple of useful links:

* Phase 1 clinical results:[https://ir.corbuspharma.com/news-events/press-releases/detail/458](https://ir.corbuspharma.com/news-events/press-releases/detail/458)
* SEC presentation with weight-loss graphs and safety data:[https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001193125-26-097582/crbp-ex99\_2.htm](https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001193125-26-097582/crbp-ex99_2.htm)
* CANYON-1 trial update:[https://www.sec.gov/Archives/edgar/data/1595097/000119312526153923/crbp-20260414.htm](https://www.sec.gov/Archives/edgar/data/1595097/000119312526153923/crbp-20260414.htm)

I'm long because I think the market is pricing CRBP as if the obesity program probably fails. The reason for this assumption is that their current market cap is around the cash at hand and they also have phase 3 cancer drug in the pipeline which by itself could/should be worth a lot more than the current valuation.

If the upcoming data confirm the early efficacy signal **and** show that Corbus has solved the historical CB1 safety problem, I think investors will have to reassess what this asset could ultimately be worth. And one way to look at the possible upside is to check what happened to Novo when their CB1 drug failed in 2024. The company lost 20-30 **billion** in market cap almost immediately meaning something similar but to the other direction could also possibly happen.

Furthermore this is an oral drug and almost the only new MOA potentially coming to market in addition to huge amount of different incretin agonist drugs already in the market or coming to market. Around 60 percent of patients discontinue GLPs (and other incretin agonists) within the first year (not working, intolerance etc) so there's also a clear and growing need for drugs with different MOA. And there's also a possibility of combination treatment since the incretin agonists and this drug work through different mechanisms.

Curious what everyone else thinks. Am I missing something in the CB1 story, or is this one of the most interesting asymmetric catalysts heading into September?

As already said I own the shares of the company for the reasons described above.